## Rahul Aggarwal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4668050/publications.pdf

Version: 2024-02-01

840585 752573 21 452 11 20 citations h-index g-index papers 22 22 22 439 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. Hypertension, 2021, 78, 1719-1726.	1.3	117
2	The MELD-Plus: A generalizable prediction risk score in cirrhosis. PLoS ONE, 2017, 12, e0186301.	1.1	51
3	Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS ONE, 2019, 14, e0213680.	1.1	47
4	Association Between the Proportion of Black Patients Cared for at Hospitals and Financial Penalties Under Value-Based Payment Programs. JAMA - Journal of the American Medical Association, 2021, 325, 1219.	3.8	46
5	Diabetes Screening by Race and Ethnicity in the United States: Equivalent Body Mass Index and Age Thresholds. Annals of Internal Medicine, 2022, 175, 765-773.	2.0	27
6	The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0253576.	1.1	26
7	Colchicine use in patients with COVID-19: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0261358.	1.1	21
8	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiology, 2021, 6, 1415.	3.0	19
9	Intensive Blood Pressure Targets for Diabetic and Other High-Risk Populations. Hypertension, 2018, 71, 833-839.	1.3	17
10	Development of an Algorithm to Identify Patients with Physician-Documented Insomnia. Scientific Reports, 2018, 8, 7862.	1.6	15
11	Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009099.	1.6	14
12	Prevalence of angina and use of medical therapy among US adults: A nationally representative estimate. American Heart Journal, 2020, 228, 44-46.	1.2	8
13	Generalizability of DAPA-CKD to the United States. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007875.	0.9	7
14	Generalizability of FIGAROâ€DKD and FIDELIOâ€DKD Trial Criteria to the US Population Eligible for Finerenone. Journal of the American Heart Association, 2022, 11, e025079.	1.6	7
15	Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. Progress in Cardiovascular Diseases, 2021, 68, 97-98.	1.6	6
16	Comparison of Medicare Advantage vs Traditional Medicare for Health Care Access, Affordability, and Use of Preventive Services Among Adults With Low Income. JAMA Network Open, 2022, 5, e2215227.	2.8	6
17	U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. Journal of the American College of Cardiology, 2020, 76, 2907-2910.	1.2	5
18	Association of the Medicare Value-Based Purchasing Program With Changes in Patient Care Experience at Safety-net vs Non–Safety-net Hospitals. JAMA Health Forum, 2022, 3, e221956.	1.0	5

#	Article	IF	CITATIONS
19	In-Hospital Mortality for Inpatient Percutaneous Coronary Interventions in the United States. American Journal of Cardiology, 2021, 159, 30-35.	0.7	4
20	Heart failure and the discrepancy between trials of intensive blood pressure management: an analysis of individual patient data. Clinical Research in Cardiology, 2018, 107, 565-569.	1.5	2
21	Acute pulmonary embolism following recent hospitalization or surgery. Journal of Thrombosis and Thrombolysis, 2021, 52, 189-199.	1.0	2